Loading
A phase 2 trial of Brexucabtagene autoleucel, Cyclophosphamide, Fludarabine in mantle cell lymphoma, run by Kite, A Gilead Company, active and no longer recruiting.
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia is a phase 2 interventional study registered as NCT06253663 by Kite, A Gilead Company, with 25 participants enrolled, started 2024-03-18 and due to reach its primary completion in 2027-07. Interventions recorded: KTE-X19, Cyclophosphamide, Fludarabine. Conditions listed: Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Brexucabtagene autoleucel, Gilead Sciences (incl. Kite), Mantle cell lymphoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/